title: Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma.
abstract: We aimed to investigate the molecular mechanisms of DYRK2 and the HCC sensitivity to Oxaliplatin in DYRK2-depleted HCC cells. HCC tissue specimens were obtained from 86 HCC patients during hepatectomy. We used immunohistochemistry and western blot to analyze DYRK2 expression in HCC tissues and cell lines, and used siRNA transfection to decrease DYRK2 expression in HCC cells. Flow cytometry and CCK-8 assay were detected in cell cycle progression, cell proliferation and the efficacy of Oxaliplatin, DYRK2 was down-regulated in HCC tissues, compared with adjacent nontumor ones. The significant correlation between DYRK2 expression and clinicopathologic factors was apparently shown in the immunohistochemical and statistical analyses. The expression of DYRK2 was significantly associated with histological grade of HCC patients. Univariate and multivariate survival analyses revealed that DYRK2 was a significant predictor for overall survival of HCC patients. The depletion of DYRK2 promoted HCC cell proliferation, and increased resistance to Oxaliplatin. These data showed that the downregulated expression of DYRK2 in HCC tumor tissues could promote the proliferation of HCC cells. In addition, reducing DYRK2 expression was associated with poor prognosis and Oxaliplatin resistance in HCC.
authors.affiliation: Department of Medical Oncology, the Second Peoples Hospital of Nan Tong, 43 Tangzha Xinglong Road, Nantong 226002, Jiangsu Province, People's Republic of China.
authors.forename: Xiubing
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Radiotherapy, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, Jiangsu Province, People's Republic of China.
authors.forename: Pan
authors.initials: P
authors.lastname: Xu
authors.affiliation: Department of Gastroenterology, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, Jiangsu Province, People's Republic of China.
authors.forename: Wenkai
authors.initials: W
authors.lastname: Ni
authors.affiliation: Department of Medical Oncology, the Second Peoples Hospital of Nan Tong, 43 Tangzha Xinglong Road, Nantong 226002, Jiangsu Province, People's Republic of China.
authors.forename: Hui
authors.initials: H
authors.lastname: Fan
authors.affiliation: Department of Medical Oncology, the Second Peoples Hospital of Nan Tong, 43 Tangzha Xinglong Road, Nantong 226002, Jiangsu Province, People's Republic of China.
authors.forename: Jian
authors.initials: J
authors.lastname: Xu
authors.affiliation: Department of Medical Oncology, the Second Peoples Hospital of Nan Tong, 43 Tangzha Xinglong Road, Nantong 226002, Jiangsu Province, People's Republic of China.
authors.forename: Yongmei
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Pathogen Biology, Jiangsu Province Key Laboratory for Information and Molecular Drug Target, Nantong University, 9 Qiangyuan Road, Nantong 226019, Jiangsu Province, People's Republic of China.
authors.forename: Wei
authors.initials: W
authors.lastname: Huang
authors.affiliation: Department of Pathogen Biology, Jiangsu Province Key Laboratory for Information and Molecular Drug Target, Nantong University, 9 Qiangyuan Road, Nantong 226019, Jiangsu Province, People's Republic of China.
authors.forename: Shumin
authors.initials: S
authors.lastname: Lu
authors.affiliation: Department of Pathogen Biology, Jiangsu Province Key Laboratory for Information and Molecular Drug Target, Nantong University, 9 Qiangyuan Road, Nantong 226019, Jiangsu Province, People's Republic of China.
authors.forename: Li
authors.initials: L
authors.lastname: Liang
authors.affiliation: Department of Gastroenterology, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, Jiangsu Province, People's Republic of China.
authors.forename: Jinxia
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Radiotherapy, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, Jiangsu Province, People's Republic of China. Electronic address: chenby1954chen@163.com.
authors.forename: Buyou
authors.initials: B
authors.lastname: Chen
authors.affiliation: Department of Medical Oncology, the Second Peoples Hospital of Nan Tong, 43 Tangzha Xinglong Road, Nantong 226002, Jiangsu Province, People's Republic of China. Electronic address: shiweidong2015@163.com.
authors.forename: Weidong
authors.initials: W
authors.lastname: Shi
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015153:Blotting, Western; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D015536:Down-Regulation; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D005260:Female; D005434:Flow Cytometry; D055785:Gene Knockdown Techniques; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D011379:Prognosis; D016016:Proportional Hazards Models; D017346:Protein Serine-Threonine Kinases / Q000096:biosynthesis*; D011505:Protein-Tyrosine Kinases / Q000096:biosynthesis*; D055815:Young Adult; D000097603:Dyrk Kinases
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D017346:Protein Serine-Threonine Kinases; D011505:Protein-Tyrosine Kinases; D000097603:Dyrk Kinases
keywords: DYRK2; Hepatocellular carcinoma; Oxaliplatin resistance; Poor prognosis